While receptor heterogeneity holds true for PVR, the interplay between the receptors i.e. TIGIT blocking CD226 mediated co-stimulation, allows us to envision developing PVR as a dual functioning therapeutic with potential utilization in both cancer and autoimmune therapy. This evidence concerns the gene TIGIT and cancer.